基于单克隆抗体的光学分子成像探针：化学、生物学和药理学方面的考量与注意事项
Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.
作者信息
Kobayashi Hisataka, Choyke Peter L, Ogawa Mikako
机构信息
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
出版信息
Curr Opin Chem Biol. 2016 Aug;33:32-8. doi: 10.1016/j.cbpa.2016.05.015. Epub 2016 Jun 6.
Abstract
The monoclonal antibody (mAb) has proven to be a good platform for designing specific molecular imaging probes due to its superior binding specificity. Several optical imaging probes have been developed for surgical navigation in patients and are in early phase clinical trials. However, an inherent limitation of using the mAb is its pharmacokinetics which result in a prolonged circulating half-life and slow clearance from the body. This results in undesirable target to background ratios during imaging. In this review, we first describe the mAb as a platform material for optical probe design and then discuss optimizing the design of monoclonal antibody-based optical molecular imaging probes by focusing on chemistry, biology and pharmacology.
摘要
由于其卓越的结合特异性，单克隆抗体（mAb）已被证明是设计特异性分子成像探针的良好平台。已经开发了几种用于患者手术导航的光学成像探针，并且正处于早期临床试验阶段。然而，使用单克隆抗体的一个固有局限性是其药代动力学，这导致循环半衰期延长和从体内清除缓慢。这在成像过程中导致不理想的靶标与背景比率。在本综述中，我们首先将单克隆抗体描述为光学探针设计的平台材料，然后通过关注化学、生物学和药理学来讨论优化基于单克隆抗体的光学分子成像探针的设计。
相似文献
1
Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.
Curr Opin Chem Biol. 2016 Aug;33:32-8. doi: 10.1016/j.cbpa.2016.05.015. Epub 2016 Jun 6.
2
Optimizing the bioavailability of small molecular optical imaging probes by conjugation to an albumin affinity tag.
J Control Release. 2014 Jul 28;186:32-40. doi: 10.1016/j.jconrel.2014.04.053. Epub 2014 May 9.
3
Exploring the Influence of Different Albumin Binders on Molecular Imaging Probe Distribution.
Mol Pharm. 2021 Jul 5;18(7):2574-2585. doi: 10.1021/acs.molpharmaceut.1c00064. Epub 2021 May 28.
4
Optimizing probes to image cleared tissue.
Nat Methods. 2016 Feb 25;13(3):205-9. doi: 10.1038/nmeth.3774.
5
Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.
Mol Pharm. 2017 Oct 2;14(10):3391-3398. doi: 10.1021/acs.molpharmaceut.7b00420. Epub 2017 Aug 30.
6
Techniques for molecular imaging probe design.
Mol Imaging. 2011 Dec;10(6):407-19.
7
(99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.
Bioorg Med Chem. 2016 Mar 15;24(6):1209-15. doi: 10.1016/j.bmc.2016.01.046. Epub 2016 Jan 29.
8
Effect of charge localization on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates.
Mol Biosyst. 2016 Oct 20;12(10):3046-56. doi: 10.1039/c6mb00371k. Epub 2016 Jul 25.
9
Impact of C4'-O-Alkyl Linker on in Vivo Pharmacokinetics of Near-Infrared Cyanine/Monoclonal Antibody Conjugates.
Mol Pharm. 2015 Sep 8;12(9):3303-11. doi: 10.1021/acs.molpharmaceut.5b00472. Epub 2015 Aug 18.
10
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.
Chem Soc Rev. 2011 Sep;40(9):4626-48. doi: 10.1039/c1cs15077d. Epub 2011 May 23.
引用本文的文献
1
Molecular imaging of gastrointestinal stromal tumor using anti-c-KIT antibody and its fragments.
J Gastroenterol. 2025 May 28. doi: 10.1007/s00535-025-02264-6.
2
Imaging antigen processing and presentation in cancer.
Immunother Adv. 2025 Feb 4;5(1):ltaf002. doi: 10.1093/immadv/ltaf002. eCollection 2025.
3
Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models.
J Clin Med. 2024 Oct 18;13(20):6211. doi: 10.3390/jcm13206211.
4
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis.
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):1149-1165. doi: 10.1007/s00259-024-06950-0. Epub 2024 Oct 24.
5
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.
Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.
6
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer.
Front Oncol. 2024 Apr 30;14:1379738. doi: 10.3389/fonc.2024.1379738. eCollection 2024.
7
Fluorescent Probes for Imaging in Humans: Where Are We Now?
ACS Nano. 2023 Oct 24;17(20):19478-19490. doi: 10.1021/acsnano.3c03564. Epub 2023 Oct 3.
8
Evaluation of nimotuzumab Fab as an optical imaging agent in EGFR positive cancers.
Sci Rep. 2023 Jul 7;13(1):10990. doi: 10.1038/s41598-023-37873-9.
9
Peptides for diagnosis and treatment of ovarian cancer.
Front Oncol. 2023 May 5;13:1135523. doi: 10.3389/fonc.2023.1135523. eCollection 2023.
10
Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Current Use and Future Recommendations.
Cancers (Basel). 2023 Jan 20;15(3):652. doi: 10.3390/cancers15030652.
本文引用的文献
1
Impact of C4'-O-Alkyl Linker on in Vivo Pharmacokinetics of Near-Infrared Cyanine/Monoclonal Antibody Conjugates.
Mol Pharm. 2015 Sep 8;12(9):3303-11. doi: 10.1021/acs.molpharmaceut.5b00472. Epub 2015 Aug 18.
2
In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.
Sci Rep. 2015 Jun 29;5:10169. doi: 10.1038/srep10169.
3
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.
Clin Cancer Res. 2015 Aug 15;21(16):3658-66. doi: 10.1158/1078-0432.CCR-14-3284. Epub 2015 Apr 22.
4
Minibody-indocyanine green based activatable optical imaging probes: the role of short polyethylene glycol linkers.
ACS Med Chem Lett. 2014 Jan 17;5(4):411-5. doi: 10.1021/ml400533y. eCollection 2014 Apr 10.
5
Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.
Mol Oncol. 2014 May;8(3):620-32. doi: 10.1016/j.molonc.2014.01.006. Epub 2014 Jan 22.
6
Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging.
J Biomed Opt. 2013 Oct;18(10):101304. doi: 10.1117/1.JBO.18.10.101304.
7
Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes.
Bioconjug Chem. 2013 May 15;24(5):811-6. doi: 10.1021/bc400050k. Epub 2013 May 3.
8
Targeted zwitterionic near-infrared fluorophores for improved optical imaging.
Nat Biotechnol. 2013 Feb;31(2):148-53. doi: 10.1038/nbt.2468. Epub 2013 Jan 6.
9
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.
Nat Med. 2011 Nov 6;17(12):1685-91. doi: 10.1038/nm.2554.
10
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.
Bioconjug Chem. 2011 Aug 17;22(8):1700-5. doi: 10.1021/bc2002715. Epub 2011 Jul 27.
Zotero 插件